HUP0402371A2 - Novel 125-i-labeled amino-quinoline derivatives - Google Patents

Novel 125-i-labeled amino-quinoline derivatives

Info

Publication number
HUP0402371A2
HUP0402371A2 HU0402371A HUP0402371A HUP0402371A2 HU P0402371 A2 HUP0402371 A2 HU P0402371A2 HU 0402371 A HU0402371 A HU 0402371A HU P0402371 A HUP0402371 A HU P0402371A HU P0402371 A2 HUP0402371 A2 HU P0402371A2
Authority
HU
Hungary
Prior art keywords
novel
quinoline derivatives
labeled amino
labeled
amino
Prior art date
Application number
HU0402371A
Other languages
English (en)
Inventor
Geza Dr Timar
Geza Toth
Csaba Toemboely
Kinga Boer
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Priority to HU0402371A priority Critical patent/HUP0402371A2/hu
Publication of HU0402371D0 publication Critical patent/HU0402371D0/hu
Priority to BRPI0517816-9A priority patent/BRPI0517816A/pt
Priority to PCT/HU2005/000120 priority patent/WO2006051341A1/en
Priority to EP05806497A priority patent/EP1814857B1/en
Priority to JP2007540727A priority patent/JP2008519816A/ja
Priority to CA002588073A priority patent/CA2588073A1/en
Priority to CN2005800388317A priority patent/CN101056859B/zh
Priority to DE602005023334T priority patent/DE602005023334D1/de
Priority to AU2005303544A priority patent/AU2005303544B2/en
Priority to RU2007122396/04A priority patent/RU2379290C2/ru
Priority to AT05806497T priority patent/ATE479660T1/de
Priority to KR1020077010909A priority patent/KR20070084202A/ko
Priority to MX2007005768A priority patent/MX2007005768A/es
Publication of HUP0402371A2 publication Critical patent/HUP0402371A2/hu
Priority to IL182971A priority patent/IL182971A0/en
Priority to US11/748,098 priority patent/US7964731B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
HU0402371A 2004-11-15 2004-11-15 Novel 125-i-labeled amino-quinoline derivatives HUP0402371A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
HU0402371A HUP0402371A2 (en) 2004-11-15 2004-11-15 Novel 125-i-labeled amino-quinoline derivatives
MX2007005768A MX2007005768A (es) 2004-11-15 2005-11-09 Derivados de quinolina marcados en forma isotopica en la forma de ligandos de receptor de adenosina a3.
CN2005800388317A CN101056859B (zh) 2004-11-15 2005-11-09 作为腺苷a3受体配体的同位素标记的喹啉衍生物
AU2005303544A AU2005303544B2 (en) 2004-11-15 2005-11-09 Isotopically marked quinoline derivatives as adenosin A3 receptor ligands
EP05806497A EP1814857B1 (en) 2004-11-15 2005-11-09 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands
JP2007540727A JP2008519816A (ja) 2004-11-15 2005-11-09 アデノシンａ３受容体リガンドとしての、同位体標識されたキノリン誘導体
CA002588073A CA2588073A1 (en) 2004-11-15 2005-11-09 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands
BRPI0517816-9A BRPI0517816A (pt) 2004-11-15 2005-11-09 derivados de quinolina isotopicamente marcados como ligantes do receptor a3 de adenosina
DE602005023334T DE602005023334D1 (de) 2004-11-15 2005-11-09 Isotopenmarkierte chinolinderivate als liganden des adenosin-a3-rezeptors
PCT/HU2005/000120 WO2006051341A1 (en) 2004-11-15 2005-11-09 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands
RU2007122396/04A RU2379290C2 (ru) 2004-11-15 2005-11-09 Изотопно-меченые производные хинолина, выступающие в качестве лигандов аденозинового рецептора a3
AT05806497T ATE479660T1 (de) 2004-11-15 2005-11-09 Isotopenmarkierte chinolinderivate als liganden des adenosin-a3-rezeptors
KR1020077010909A KR20070084202A (ko) 2004-11-15 2005-11-09 아데노신 ａ3 수용체 리간드로서의 동위원소로 표지된퀴놀린 유도체
IL182971A IL182971A0 (en) 2004-11-15 2007-05-03 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands
US11/748,098 US7964731B2 (en) 2004-11-15 2007-05-14 Isotopically marked quinoline derivatives as adenosin A3 receptor ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0402371A HUP0402371A2 (en) 2004-11-15 2004-11-15 Novel 125-i-labeled amino-quinoline derivatives

Publications (2)

Publication Number Publication Date
HU0402371D0 HU0402371D0 (en) 2005-03-29
HUP0402371A2 true HUP0402371A2 (en) 2006-09-28

Family

ID=89985606

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402371A HUP0402371A2 (en) 2004-11-15 2004-11-15 Novel 125-i-labeled amino-quinoline derivatives

Country Status (15)

Country Link
US (1) US7964731B2 (hu)
EP (1) EP1814857B1 (hu)
JP (1) JP2008519816A (hu)
KR (1) KR20070084202A (hu)
CN (1) CN101056859B (hu)
AT (1) ATE479660T1 (hu)
AU (1) AU2005303544B2 (hu)
BR (1) BRPI0517816A (hu)
CA (1) CA2588073A1 (hu)
DE (1) DE602005023334D1 (hu)
HU (1) HUP0402371A2 (hu)
IL (1) IL182971A0 (hu)
MX (1) MX2007005768A (hu)
RU (1) RU2379290C2 (hu)
WO (1) WO2006051341A1 (hu)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
RU2278112C2 (ru) * 2001-05-31 2006-06-20 Санофи-Авентис Производные аминохинолина и аминопиридина и их применение в качестве лигандов аденозина a3

Also Published As

Publication number Publication date
WO2006051341A1 (en) 2006-05-18
CN101056859A (zh) 2007-10-17
RU2379290C2 (ru) 2010-01-20
RU2007122396A (ru) 2008-12-20
JP2008519816A (ja) 2008-06-12
CN101056859B (zh) 2010-05-05
MX2007005768A (es) 2007-07-16
US7964731B2 (en) 2011-06-21
EP1814857B1 (en) 2010-09-01
EP1814857A1 (en) 2007-08-08
BRPI0517816A (pt) 2008-10-21
AU2005303544B2 (en) 2011-06-02
CA2588073A1 (en) 2006-05-18
ATE479660T1 (de) 2010-09-15
HU0402371D0 (en) 2005-03-29
IL182971A0 (en) 2007-08-19
AU2005303544A1 (en) 2006-05-18
KR20070084202A (ko) 2007-08-24
US20080027225A1 (en) 2008-01-31
DE602005023334D1 (de) 2010-10-14

Similar Documents

Publication Publication Date Title
TWI369356B (en) Tetrahydropyridoindole derivatives
IL180481A0 (en) Aryl-pyridine derivatives
HK1105971A1 (en) Pyrrazolo-pyrimidine derivatives
IL180331A0 (en) 3-carbamoyl - 2 - pyridone derivative
IL178884A0 (en) Novel cis-imidazolines
IL179730A0 (en) Novel cis-imidazolines
AP2074A (en) New 4-benzylidene-piperidin derivatives
IL183140A0 (en) Substituted benzoquinolizine derivatives
IL177204A0 (en) Novel 4-benzimidazol -2-ylpyridazin -3- one derivatives
ZA200703172B (en) Imidazo-benzodiazepine derivatives
HK1101638A1 (en) New pyridothienopyrimidine derivatives
HK1100002A1 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
IL183141A0 (en) New pyridothienopyrimidine derivatives
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
HK1100775A1 (en) 4-Amino-5-cyanopyrimidine derivatives
GB0414272D0 (en) OsK1 derivatives
IL182001A0 (en) 2-acylaminothiazole derivatives
HUP0402371A2 (en) Novel 125-i-labeled amino-quinoline derivatives
GB0408865D0 (en) Novel benzoxazocines
GB0405905D0 (en) Azaquinazoline derivatives
GB0422397D0 (en) 3-Cyano-Quinoline derivatives
GB0408864D0 (en) Novel benzoxazocines
GB0408862D0 (en) Novel benzoxazocines
GB0408863D0 (en) Novel benzoxazocines

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished